The White House is employing the Defense Production Act of 1950 (DPA) in response to the Coronavirus Disease 2019 (COVID-19) pandemic to facilitate the production and availability of essential goods, supplies, and services. This Insight considers recent DPA actions and associated policy considerations for Congress. It is a companion to CRS Insights IN11337, IN11280, and IN11231. See CRS Report R43767 for a more in-depth discussion of DPA history and authorities.

New DPA Actions in Response to COVID-19

Since April 15, eight DPA actions have been made public:

These actions were made publicly available, but may not be exhaustive. There are no statutory reporting requirements for DPA actions.

DPA Issues for Congress

The Administration has employed the DPA selectively, focusing on individual companies (e.g., GM, 3M) or industry sub-sectors (e.g., meat processing). There have been sporadic DPA efforts, and an opaque process, in response to complaints from Congress and some governors regarding ongoing shortages of personal protective equipment, testing supplies, and other such resources. The Administration's announced actions have primarily framed the DPA as a coercive instrument (the President called the DPA a "tremendous hammer") with relatively narrow application.

Recent DPA actions present a number of issues that may be of interest to Congress:

Policy Considerations

Given these issues, Congress may wish to consider several policy options: